Vol. 1 No. 10 (2021)
Reimbursement Reviews

Daunorubicin and Cytarabine Liposome (Vyxeos)

Published October 29, 2021

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses dunorubicin and cytarabine liposome for injection, 44 mg daunorubicin and 100 mg cytarabine per vial, IV infusion
  • Indication: Treatment of adults with newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes